Anti-amyloid monoclonal antibodies produced marked lowering of brain β-amyloid plaque and slowing of clinical decline as measured by the Clinical Dementia Rating–Sum of Boxes and other clinical and functional measures.

Anti-amyloid monoclonal antibodies produce amyloid-related imaging abnormalities (ARIA) that are usually asymptomatic but may be severe and require anticipatory management.

Slowing of clinical decline has been observed when the β-amyloid lowering reaches 15–25 centiloids, a common measure of β-amyloid abundance in the brain.